INFO	Title	Neuroblastoma (NBL) Data Dictionary																														
INFO	Name	nbl_v1.2																														
INFO	Release Notes	https://github.com/chicagopcdc/d4cg-modeling/tree/main/pcdc/nbl/nbl_v1.2																														
INFO	Parent Data Model	pcdc_v1.8																														
INFO	License	Creative Commons Attribution-NonCommercial 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/)																														
INFO	D4CG Data Modeling Wiki	https://docs.pedscommons.org/																														
INFO	Disease Consortium Information	https://commons.cri.uchicago.edu/pcdc/																														
INFO	Description	The NBL data dictionary is a consensus data schema built by an international group of pediatric neuroblastoma experts and maintained by Data for the Common Good (D4CG) at the University of Chicago in collaboration with the International Neuroblastoma Risk Group (INRG). It is based on the collective requirements of its contributors.																														
INFO	Total Variables	75																														
																																
RowType	VariableName	DataType	Tier	VariableDescription	VariableCode	PermissibleValue	ValueDescription	ValueCode	Implementation Notes	Mappings																						
																																
TD	Subject Characteristics																															
TG	One row per subject per treatment arm																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_																								
VD	AGE_AT_ENROLLMENT	Number		The age (in days) when the subject enrolled in the study.	ncit:C168843	_undefined_	_undefined_	_undefined_		New VD																						
VD	YEAR_AT_ENROLLMENT	Number		The year at which a subject enrolled in a study.	ncit:C177353	_undefined_	_undefined_	_undefined_		New VD																						
VD	STUDY_ID	Code		A sequence of characters used to identify, name, or characterize the study.		_undefined_	_undefined_	_undefined_	ConsortiumNote: Some patients will have frontline data already in PCDC, we want to link rather than duplicate data for these patients.																							
PD						BEACON																										
VD	TREATMENT_ARM	Code		A specific treatment plan within a clinical trial that describes the activities a subject will be involved in as he or she progresses through the study.	C15538	_undefined_	_undefined_	_undefined_																								
PD						Active Comparator: Temozolomide			D4CGNote: STUDY_ID = "BEACON"																							
PD						Experimental: Bevacizumab + Temozolomide			D4CGNote: STUDY_ID = "BEACON"																							
PD						Experimental: Irinotecan + Temozolomide			D4CGNote: STUDY_ID = "BEACON"																							
PD						Experimental: Bevacizumab + Irinotecan + Temozolomide			D4CGNote: STUDY_ID = "BEACON"																							
PD						Experimental: Temozolomide + Topotecan			D4CGNote: STUDY_ID = "BEACON"																							
PD						Experimental: Bevacizumab + Temozolomide + Topotecan			D4CGNote: STUDY_ID = "BEACON"																							
PD						Experimental: Dinutuximab beta + Temozolomide			D4CGNote: STUDY_ID = "BEACON"																							
PD						Experimental: Dinutuximab beta + Temozolomide + Topotecan			D4CGNote: STUDY_ID = "BEACON"																							
PD						Other: Dinutuximab beta + Topotecan + Cyclophosphamide			D4CGNote: STUDY_ID = "BEACON"																							
VD	AGE_AT_CENSOR_STATUS	Number		The age (in days) of the subject at the time of the event censor status.		_undefined_	_undefined_	_undefined_																								
VD	EFS_CENSOR_STATUS	Code		The status of individuals in a study when their outcome (event occurrence or time to event) is censored or not censored at the time of analysis or data collection. Censoring occurs when an individual has not experienced the event of interest by the end of the study period or at the time of data analysis, often because they were lost to follow-up, withdrew from the study, or the study ended before the event could occur. In event-free survival analysis, these censored individuals are included in the analysis up to the point of censoring and are essential for estimating survival probabilities and analyzing the time to events.		_undefined_	_undefined_	_undefined_																								
PD						Subject is censored (i.e. has had no events(s))	The status of a participant or subject in a study whose event or outcome of interest has not yet occurred or has not been observed within the study's follow-up period. Censoring occurs when the event of interest has not happened to a participant by the end of the study or when they are lost to follow-up before the event occurs.	C118962																								
PD						Subject has had one or more events	The patient has experienced the event of interest within the study period and has reached the endpoint being evaluated, such as disease progression, relapse, recurrence, or death, and their time to event can be accurately recorded and analyzed.																									
																																
																																
TD	Disease Phase Timing																															
TG	One row per subject per disease phase																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_																								
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813																								
PD						Relapse/Progression	Either the return of the disease or the progression of the disease.	C174991		New PD																						
PD						Refractory	Not responding to treatment.	C38014																								
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_																								
VD	AGE_AT_DISEASE_PHASE	Number		Age of subject (in days) at the end of the treatment course.	C168851	_undefined_	_undefined_	_undefined_																								
VD	YEAR_AT_DISEASE_PHASE	Number		Age of subject (in days) at the disease phase.	C168972	_undefined_	_undefined_	_undefined_																								
																																
																																
TD	Course Timing									New TD																						
TG	One row per subject per course or cycle 																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	CYCLE_NUMBER	Number		Cycle Number	C166208	_undefined_	_undefined_	_undefined_		New VD																						
VD	AGE_AT_CYCLE_START	Number		Age in Days at Cycle Start		_undefined_	_undefined_	_undefined_	ConsortiumNote: Only available for trail therapy, not for frontline	New VD																						
VD	AGE_AT_CYCLE_END	Number		Age in Days at Cycle End		_undefined_	_undefined_	_undefined_	ConsortiumNote: Only available for trail therapy, not for frontline	New VD																						
																																
																																
TD	Demographics																															
TG	One row per subject																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	SEX	Code		The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female.	ncit:C28421	_undefined_	_undefined_	_undefined_																								
PD						Male	A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both.	C20197																								
PD						Female	A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both.	C16576																								
PD						Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	C17998																								
PD						Not Reported	Not provided or available.	C43234																								
																																
																																
TD	Survival Characteristics																															
TG	One row per subject per LKSS																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	AGE_AT_LKSS	Number		The age (in days) when the last known survival status of the subject was captured.		_undefined_	_undefined_	_undefined_																								
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_																								
PD						Relapse/Progression	Either the return of the disease or the progression of the disease.	C174991		New PD																						
PD						Refractory	Not responding to treatment.	C38014																								
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_																								
VD	LKSS	Code		The last known survival status of the subject.	C168931	_undefined_	_undefined_	_undefined_																								
PD						Alive	Showing characteristics of life; displaying signs of life.	C37987																								
PD						Dead	The cessation of life.	C28554																								
VD	CAUSE_OF_DEATH	Code		The circumstance or condition that results in the death of a living being.	C81239	_undefined_	_undefined_	_undefined_																								
PD						Disease Progression																										
PD						Secondary Malignancy				New PD																						
PD						Treatment-Related Mortality	A death that is considered to be causally linked to a treatment.	C166165																								
PD						Unrelated to Disease or Treatment				New PD																						
																																
																																
TD	Tumor Assessment																															
TG	One row per subject per tumor assessment per tumor site																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	AGE_AT_TUMOR_ASSESSMENT	Number		Age of subject (in days) at tumor assessment.	ncit:C174997	_undefined_	_undefined_	_undefined_																	AGE_AT_TUMOR_ASSESSMENT	Number	n/a	Age in Days at Tumor Assessment		_undefined_	_undefined_	_undefined_
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_																								
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813																								
PD						Relapse/Progression	Either the return of the disease or the progression of the disease.	C174991		New PD																						
PD						Refractory	Not responding to treatment.	C38014																								
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_																								
VD	TUMOR_CLASSIFICATION	Code		The classification of a tumor based primarily on histopathological characteristics.	C174459	_undefined_	_undefined_	_undefined_																								
PD						Primary	A tumor at the original site of origin.	C8509																								
PD						Metastatic	A tumor that has spread from its original (primary) site of growth to another site, close to or distant from the primary site.  Metastasis is characteristic of advanced malignancies, but in rare instances can be seen in neoplasms lacking malignant morphology.	C3261																								
VD	TUMOR_STATE	Code		A condition or state of a tumor at a particular time and a particular tumor site.	C96643	_undefined_	_undefined_	_undefined_																								
PD						Present	Being or existing in a specified place or at the specified time.	C25626																								
PD						Absent	Not existing in a specified place at a specified time.	C48190																								
PD						Unknown	Not known, observed, recorded; or reported as unknown by the data contributor.	C17998																								
VD	TUMOR_SITE	Code		The anatomic site of the tumor.	C157120	_undefined_	_undefined_	_undefined_																								
PD						Central Nervous System	The part of the nervous system that consists of the brain, spinal cord, and meninges.	C12438																								
PD						Distant Lymph Nodes	A lymph node located distant to the anatomic site of interest.	C106042																								
PD						Liver	A triangular-shaped organ located under the diaphragm in the right hypochondrium. It is the largest internal organ of the body, weighting up to 2 kg. Metabolism and bile secretion are its main functions. It is composed of cells which have the ability to regenerate.	C12392																								
PD						Lung	One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border.	C12468																								
PD						Adrenal Gland	A flattened, roughly triangular body resting upon the upper end of each kidney; it is one of the ductless glands furnishing internal secretions (epinephrine and norepinephrine from the medulla and steroid hormones from the cortex).	C12666																								
PD						Abdomen	The cavity located between the lungs and pelvis. It contains the lower esophagus, stomach, pancreas, intestines, liver, gallbladder and spleen.	C12664																								
PD						Neck	The region that connects the head to the rest of the body.	C13063																								
PD						Thorax	The division of the body lying between the neck and the abdomen.	C12799																								
PD						Pelvis	The bony, basin-shaped structure formed by the hipbones and the base of the backbone supporting the lower limbs in humans.	C12767																								
PD						Bone Marrow	The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.	C12431																								
PD						Bone	The structural organ comprised of specialized connective tissue that forms the skeletal components of the body.	C12366																								
PD						Skin	An organ that constitutes the external surface of the body. It consists of the epidermis, dermis, and skin appendages.	C12470																								
VD	TUMOR_SITE_OTHER	String		Specify the "Other" Tumor Site.		_undefined_	_undefined_	_undefined_																								
																																
																																
TD	Staging																															
TG	One row per subject per staging assessment																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_																								
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813																								
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_																								
VD	STAGE	Code		The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.	C16899	_undefined_	_undefined_	_undefined_																								
PD						INRGSS, Stage L1																										
PD						INRGSS, Stage L2																										
PD						INRGSS, Stage M																										
PD						INRGSS, Stage MS																										
																																
																																
TD	Molecular Analysis																															
TG	One row per subject per molecular analysis method per molecular abnormality																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	AGE_AT_MOLECULAR_ANALYSIS	Number		Age of subject (in days) when molecular analysis was performed.	C168848	_undefined_	_undefined_	_undefined_																								
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_																								
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813																								
PD						Relapse/Progression	Either the return of the disease or the progression of the disease.	C174991		New PD																						
PD						Refractory	Not responding to treatment.	C38014																								
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_																								
VD	MOLECULAR_ABNORMALITY	Code		The type of variation detected by this genetic analysis.		_undefined_	_undefined_	_undefined_																								
PD						MYCN Amplification	An increase in the number of copies of the MYCN gene, resulting in the overexpression of the MYCN protein. MYCN amplification is commonly associated with aggressive neuroblastoma and can be a predictor of poor prognosis and a target for specific therapies.																									
VD	GENE1	String		The gene symbol that represents either a single gene that has a mutation or the gene that comprises the 5' portion of the coding sequence involved in a fusion gene mutation.	C173595	_undefined_	_undefined_	_undefined_																								
VD	COPY_NUMBER_STATUS	Code		The status of the copy number.		_undefined_	_undefined_	_undefined_																								
PD						Gain	The acquisition of additional copies of a specific DNA segment, which can include entire chromosomes or smaller DNA regions. In the context of cancer, gains often refer to the increase in the number of copies of chromosomal regions or genes, which can lead to overexpression and tumor development.																									
PD						Loss	The decrease in the number of copies of a specific DNA segment, which can include entire chromosomes or smaller chromosomal regions. This can occur through deletions, where a segment of DNA is removed, or through other mechanisms that result in reduced genetic material. Loss of genetic material can lead to the absence of essential genes, loss of gene function, or reduced gene dosage, which can contribute to disease development, including cancer.																									
PD						Amplification	Amplification refers to an increase in the number of copies of a specific DNA segment, which can include genes or chromosomal regions. This genetic alteration results in the overproduction of the gene or genes located within the amplified region. In cancer, gene amplification can lead to the overexpression of oncogenes, which can drive tumor growth and contribute to cancer progression. Amplification is typically identified through genetic testing techniques such as fluorescence in situ hybridization (FISH), quantitative PCR, or array-based methods.																									
PD						No gain/loss/amplification	A genetic variation where gain, loss, or exchange of DNA results in monoallelic loss of function mutations in a diploid cell. In the context of tumor suppressor genes, where a single copy is sufficient for functionality, loss of function for the second allele is associated with tumorigenesis.	C18016																								
PD						Unknown	Reported as unknown by the data contributor.	C17998																								
																																
																																
TD	Secondary Malignant Neoplasm																															
TG	One row per subject per secondary malignancy																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	AGE_AT_SMN	Number		Age in Days at Secondary Malignant Neoplasm	C168860	_undefined_	_undefined_	_undefined_																								
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_																								
PD						Refractory	Not responding to treatment.	C38014																								
PD						Relapse/Progression	Either the return of the disease or the progression of the disease.	C174991		New PD																						
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_																								
VD	SMN	Code		Secondary Malignancy		_undefined_	_undefined_	_undefined_																								
PD						Yes	The affirmative response to a question.	C49488																								
PD						No	The non-affirmative response to a question.	C49487																								
																																
																																
TD	Stem Cell Transplant									New TD																						
TG	One row per subject per stem cell transplant																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_		New VD																						
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813		New PD																						
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_		New VD																						
VD	SCT_TYPE	Code		The type of stem cell transplant that the subject received.	C168864	_undefined_	_undefined_	_undefined_		New VD																						
PD						Autologous, Single	An autologous stem cell transplant performed once. In this procedure, a patient's own stem cells are collected, stored, and then reinfused after intensive chemotherapy or radiation therapy. The purpose is to restore the bone marrow and blood cell production that the aggressive treatment has destroyed.			New PD																						
PD						Autologous, Tandem	A series of two autologous stem cell transplants performed sequentially, usually within a few months of each other. The tandem transplant approach is designed to maximize the therapeutic effect of high-dose chemotherapy or radiation by repeating the stem cell reinfusion process, offering a more aggressive treatment option for certain cancers.			New PD																						
PD						Unknown	Reported as unknown by the data contributor.	C17998		New PD																						
PD						Not Reported	Not provided or available.	C43234		New PD																						
VD	TREATMENT_ASSIGNED	Code		Was this treatment assigned?		_undefined_	_undefined_	_undefined_		New VD																						
PD						Yes	The affirmative response to a question.	ncit:C49488		New PD																						
PD						No	The non-affirmative response to a question.	ncit:C49487		New PD																						
																																
																																
TD	Biopsy and Surgical Procedures									New TD																						
TG	One row per subject per procedure																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_		New VD																						
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813		New PD																						
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_		New VD																						
VD	PROCEDURE	Code		A categorization of surgical procedures by type or purpose.	C161601	_undefined_	_undefined_	_undefined_		New VD																						
PD						Surgical Resection				New PD																						
VD	TREATMENT_PERFORMED	Code		Was this treatment assigned?		_undefined_	_undefined_	_undefined_		New VD																						
PD						Yes	The affirmative response to a question.	ncit:C49488		New PD																						
PD						No	The non-affirmative response to a question.	ncit:C49487		New PD																						
																																
																																
TD	Total Dose								ConsortiumNote: Only reported for Induction therapy from frontline trial. Treatment given on BEACON is captured in TREATMENT_ARM in the subject_characteristics table.	New TD																						
TG	One row per subject per chemotherapy treatment																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_		New VD																						
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813		New PD																						
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_		New VD																						
VD	REGIMEN	Code		Medication Regimen		_undefined_	_undefined_	_undefined_		New VD																						
PD						GPOH Induction				New PD																						
PD						COJEC				New PD																						
PD						N7				New PD																						
PD						COJEC+TVD				New PD																						
PD						Other				New PD																						
VD	REGIMEN_OTHER	String		Medication Regimen Other (free-text)		_undefined_	_undefined_	_undefined_		New VD																						
VD	ANTINEOPLASTIC_AGENT	Code		Antineoplastic Agent	C274	_undefined_	_undefined_	_undefined_		New VD																						
PD						Dinutuximab-beta			ConsortiumNote: Anti-GD2	New PD																						
PD						Crizotinib			ConsortiumNote: Anti-ALK	New PD																						
PD						Lorlatinib			ConsortiumNote: Anti-ALK	New PD																						
PD						MIBG			ConsortiumNote: MIBG Therapy	New PD																						
VD	TREATMENT_ASSIGNED	Code		Was this treatment assigned?		_undefined_	_undefined_	_undefined_		New VD																						
PD						Yes	The affirmative response to a question.	ncit:C49488		New PD																						
PD						No	The non-affirmative response to a question.	ncit:C49487		New PD																						
																																
TD	Radiation Therapy									New TD																						
TG	One row per subject per radiation therapy																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_		New VD																						
PD						Initial Diagnosis	The first diagnosis of the individual's condition.	C156813		New PD																						
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_		New VD																						
VD	TREATMENT_ASSIGNED	Code		Was this treatment assigned?		_undefined_	_undefined_	_undefined_		New VD																						
PD						Yes	The affirmative response to a question.	ncit:C49488		New PD																						
PD						No	The non-affirmative response to a question.	ncit:C49487		New PD																						
																																
																																
TD	Subject Response									New TD																						
TG	One row per subject per response assessment																															
VD	HONEST_BROKER_SUBJECT_ID	String		The identifier assigned to the subject by the honest broker--an individual, organization or system acting for, or on behalf of, a covered entity to collect and provide health information to research investigators in such a manner whereby it would not be reasonably possible for the investigators or others to identify the corresponding patients-subjects directly or indirectly. The honest broker cannot be one of the investigators. The information provided to the investigators by the honest broker may incorporate linkage codes to permit information collation and/or subsequent inquiries (i.e., a "re-identification code"), however the information linking this re-identification code to the patient's identity must be retained by the honest broker and subsequent inquiries are conducted through the honest broker.	C168949	_undefined_	_undefined_	_undefined_		New VD																						
VD	AGE_AT_RESPONSE	Number		Age of subject (in days) when the response assessment was made.	C168856	_undefined_	_undefined_	_undefined_		New VD																						
VD	DISEASE_PHASE	Code		The phase of the cancer treatment process during which relevant observations were recorded. This variable is used across domains to frame the timing of these longitudinal observations and reduce the number of redundant variables needed to report similar concepts (see "Disease Phase Timing and Course Table" in the documentation for additional guidance).	C168878	_undefined_	_undefined_	_undefined_		New VD																						
PD						Refractory	Not responding to treatment.	C38014		New PD																						
PD						Relapse/Progression	Either the return of the disease or the progression of the disease.	C174991		New PD																						
VD	DISEASE_PHASE_NUMBER	Number		The number of the disease phase.	C173258	_undefined_	_undefined_	_undefined_		New VD																						
VD	CYCLE_NUMBER	Number		Cycle Number	C166208	_undefined_	_undefined_	_undefined_		New VD																						
VD	RESPONSE_CATEGORY	Code		The category used to assess the response to therapy.	C173306	_undefined_	_undefined_	_undefined_		New VD																						
PD						Overall Response	An assessment of the overall response of the disease to the therapy.	C96613		New PD																						
PD						Primary Site Response	The response at a primary site of a disease or condition to treatment.			New PD																						
PD						Bone Marrow Response	The response of the bone marrow to the treatment.	C173307		New PD																						
PD						Metastatic Soft Tissue and Bone Response	The evaluation of how metastatic (spreading) cancer affects and responds to treatment in soft tissues and bones. Metastatic cancer cells originate from the primary tumor and spread to other parts of the body, including soft tissues (like muscles, fat, and connective tissues) and bones. The response can be assessed through imaging studies, biopsies, and other diagnostic tests to determine changes in tumor size, density, and metabolic activity in these areas, which helps guide treatment decisions and prognosis.			New PD																						
VD	RESPONSE	Code		A standard way to measure how well a cancer patient responds to treatment.	C50995	_undefined_	_undefined_	_undefined_		New VD																						
PD						RECIST, Complete Response				New PD																						
PD						RECIST, Partial Response				New PD																						
PD						RECIST, Stable Disease				New PD																						
PD						RECIST, Progressive Disease				New PD																						
PD						INRC Park 2017, Complete Response				New PD																						
PD						INRC Park 2017, Partial Response				New PD																						
PD						INRC Park 2017, Stable Disease				New PD																						
PD						INRC Park 2017, Minor Response				New PD																						
PD						INRC Park 2017, Minimal Disease				New PD																						
PD						INRC Park 2017, Progressive Disease				New PD																						
PD						Not Evaluable				New PD																						
PD						Not Done	Indicates a task, process or examination that has either not been initiated or not been completed.	C49484		New PD																						
PD						Unknown	Reported as unknown by the data contributor.	C17998		New PD																						
PD						Not Involved	The indicated response category was not involved in the response assessment.			New PD																						
VD	MIBG_SCORE_TYPE	Code		The type of response score provided in RESPONSE_MEASUREMENT_NUMERIC		_undefined_	_undefined_	_undefined_		New VD																						
PD						MIBG SIOPEN Score	The semi-quantitative SIOPEN score evaluates skeletal meta-iodobenzylguanidine (mIBG) uptake on a 0â€“6 scale in 12 anatomical regions.			New PD																						
VD	MIBG_SCORE	Number		The numeric response of the MIBG score.		_undefined_	_undefined_	_undefined_		New VD																						